Taienkang announced that Anhui Taienkang Bioengineering Co., Ltd., the company's holding company, recently received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration and agreed to conduct clinical trials of its injectable TKB02 on adult patients with chronic immune thrombocytopenia who did not respond well to other treatments. The registered classification of this drug is Class 3.3. Up to now, no biosimilar of this type has been approved for marketing in China. Subsequent clinical trials need to be carried out and approved before they can be produced and marketed. There is uncertainty about R&D and marketing.

Taienkang announced that Anhui Taienkang Bioengineering Co., Ltd., the company's holding company, recently received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration and agreed to conduct clinical trials of its injectable TKB02 on adult patients with chronic immune thrombocytopenia who did not respond well to other treatments. The registered classification of this drug is Class 3.3. Up to now, no biosimilar of this type has been approved for marketing in China. Subsequent clinical trials need to be carried out and approved before they can be produced and marketed. There is uncertainty about R&D and marketing.